Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in xenograft models and has been successful in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
This page contains content from the copyrighted Wikipedia article "Axitinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
